immune cell News
-
Mechanism of Action Via Inovotion’s Assays
Understanding Mechanisms of Action is a key success factor in developing new anticancer drugs. It’s needed to optimize drug development, clinical trials, and regulatory approval. Inovotion’s in vivo assays provide ample access to tumors for deep analysis of the mechanisms of action including transcriptomics, metabolomics, proteomics, immune cell infiltration, histological analysis, ...
-
Hydrogen Peroxide provides Clues to Immunity, Wound Healing, Tumor Biology - Puroxi
Hydrogen peroxide isn’t just that bottled colorless liquid in the back of the medicine cabinet that’s used occasionally for cleaning scraped knees and cut fingers.It’s also a natural chemical in the body that rallies at wound sites, jump-starting immune cells into a series of events. A burst of hydrogen peroxide causes neutrophils, the immune system’s first ...
-
Roswell Park introduces “Tactiva Therapeutics” as new Biotech Spinoff Company
BUFFALO, N.Y.(WKBW) – Lieutenant Governor Kathy Hochul, Dr. Candace Johnson and a special team of doctors at Roswell Park announced the launch of a new innovative Immunotherapy Biotech Company called, Tactiva Therapeutics in front of a packed house inside Roswell’s Research Center. Tactiva will develop the latest science to lead even more effective approaches at fighting and treating ...
-
Indee Labs Announces Successful Launch of Early Access Program
Indee Labs today announced the addition of three of the largest pharmaceutical companies, multiple biotechnology companies as well as Stanford's Cell Therapy Clinic and Moffitt Cancer Center, to participate in its Early Access Program. As part of the program, each participant receives temporary access to the Indee Labs platform and team for internal research and evaluation ...
By Indee Labs
-
Synaffix Licenses CliCr Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering
Synaffix obtains exclusive rights to the CliCr® technology, to combine with its proprietary ADC platform technology CliCr® further expands the repertoire of payloads suitable for conjugation by enhancing reactivity, stability and hydrophilicity Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of ...
By Synaffix BV
-
Immunai Using Acquisition, Funding to Shift Into Functional Work
With a recently closed $60 million funding round, the acquisition of software company Dropprint Genomics, and additions to its leadership team, immune profiling firm Immunai is looking to expand its functional genomics capabilities to more directly inform immune therapy development and application. Since launching in 2018, the New York City-based company has focused its efforts on multiomic ...
By Immunai
-
Webinar #4: The CAM Assay: From Efficacy/Toxicity Studies to Mechanisms of Action Analysis
Webinar Description: Understanding the mechanisms of action of new drugs is a key success factor for efficient drug discovery. It’s necessary for: Anticipating problems relating to clinical safety Determining the site of interaction between a drug and a receptor Identifying which patients will respond to a given treatment Improving drug dosing Considering combinations or ...
-
SQZ Biotechnologies Announces Integrated Point-ofCare Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process
WATERTOWN, Mass.--(BUSINESS WIRE)-- SQZ Biotechnologies (NYSE: SQZ) announced today that the company’s rst generation, integrated point-of-care (POC) cell therapy manufacturing system demonstrated superior process performance and comparable or improved product specications relative to current clean room-based processes used in clinical development. The non-clinical studies showed that the ...
-
Cartherics granted first patent in China for multiple development candidates
Melbourne, Australia, 09 January 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. This patent is part of the family represented by the international patent ...
-
BioTech Breakthrough Recognizes Ozette as the 2022 Overall Immunology Company of the Year
We’re honored to be named the 2022 Overall Immunology Company of the Year by BioTech Breakthrough. Ozette’s computational immune profiling tech breaks through complex, highly dimensional datasets to revolutionize our understanding of the human immune system. BioTech Breakthrough recognizes Ozette for accelerating scientific collaboration with automated and interpretable single-cell ...
-
Immunai acquires single-cell data developer Dropprint Genomics to build out its immune system atlas
Shortly after raising $60 million to fuel its artificial intelligence work, aimed at digitally charting the human body’s immune system, Immunai announced it has acquired the single-cell sequencing software startup Dropprint Genomics. Previously backed by Y Combinator, the San Francisco-based Dropprint aims to provide big data and machine learning solutions to help crunch the numbers ...
By Immunai
-
Vicinivax Announces Last Patient Out In The Phase I Study With Immunotherapy Vvax001 ...
ViciniVax is pleased to report today that the last patient has completed treatment in the Phase I study with Vvax001. This study was designed to assess the safety and HPV16 E6,7-specific T-cell immune responses upon injection of 4 different doses of Vvax001 in a total of 12 subjects. Full analysis of the data is expected in Q2 2018. ...
By ViciniVax BV
-
Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid and hematologic malignancies, and TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), announced today that they have entered ...
-
Indee Labs Awarded Contract from the National Cancer Institute
Indee Labs is a biotechnology company developing the µVS Delivery SystemTM for non-viral intracellular or gene delivery. The team at Indee Labs was recently awarded a contract from the National Cancer Institute to develop the µVS Delivery SystemTM for T cell immunotherapy discovery, development and manufacturing. “T cell immunotherapies have ...
By Indee Labs
-
Indee Labs Awarded Grant from the National Institute of Allergy & Infectious Disease
Indee Labs is a biotechnology company developing the µVS Delivery SystemTM for non-viral intracellular or gene delivery. The team at Indee Labs was awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop the µVS Delivery SystemTM for modified regulatory T cells. ...
By Indee Labs
-
Ash inhalation increases risk of lung infection
Inhaling volcanic ash could weaken the body’s natural defences against infection, a recent study concludes. A team of researchers collected samples of ash from the 2010 Eyjafjallajökull volcano eruption in Iceland and, in laboratory tests, found that they reduced the ability of immune cells in lungs to fight off bacterial infections. Volcanic air pollution has often been linked to ...
-
ViciniVax announces first patient treated in Phase I study with immunotherapy Vvax001 for HPV-related precancers and cancer
ViciniVax is pleased to report today that the last patient has completed treatment in the Phase I study with Vvax001. This study was designed to assess the safety and HPV16 E6,7-specific T-cell immune responses upon injection of 4 different doses of Vvax001 in a total of 12 subjects. Full analysis of the data is expected in Q2 2018. ...
By ViciniVax BV
-
Data Driven: Immunai Adds Biocuration, European Hubs with Nebion Acquisition
Immunai has taken some important steps toward its quest to map the entire immune system by completing its second acquisition this year and bolstering its management and board with new executive and entrepreneurial expertise. Immunai has acquired the Swiss-based biocuration and data integration company Nebion for an undisclosed sum. The deal should extend Immunai’s target discovery and drug ...
By Immunai
-
A Vital Training Opportunity for CGT Manufacturing - A Global Partnership with ISCT & CMaT
The International Society for Cell & Gene Therapy (ISCT) and The National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT) led by the Georgia Institute of Technology are pleased to launch the first joint-training program of our partnership, Workforce Development in Biomanufacturing – A Global Partnership with ISCT and CMaT. Developed by ...
-
Affimed Announces Annual General Meeting of Shareholders
Heidelberg, Germany, May 24, 2022 – Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2022 Annual General Meeting of Shareholders (the “Annual Meeting”) will be held on June 22, 2022 at 09:00 a.m. CET at the ...
By Affimed GmbH
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you